Taipei, Taiwan, October 30th, 2023 – Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company will be presenting at the American Heart Association (AHA) 2023 Annual Meeting taking place in Philadelphia, PA, from November 11-13, 2023. The presentation will focus on Foresee’s first-in-class oral ALDH2 activator, FP-045, and the clinical design of Phase 2 pulmonary hypertension associated with interstitial lung disease (PH-ILD) clinical study (WINDWARD study) currently in planning.
The oral presentation entitled: "A New Therapeutic Paradigm for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Windward Phase 2 Study" details the clinical design of the FP-045 WINDWARD Phase 2 study that will be conducted in collaboration with clinical experts in the area of pulmonary hypertension and interstitial lung disease.
Bassem Elmankabadi, M.D., Foresee’s SVP of Clinical Development presenting the study, stated: “The WINDWARD Phase 2 study is designed to evaluate the safety, tolerability and efficacy of FP-045 in patients with PH-ILD. Based on the mechanism of action and body of evidence of non-clinical pharmacology data of FP-045 on pulmonary artery wall thickness, we are very hopeful about the therapeutic promise of ALDH2 activation for PH-ILD patients and confident that the readout from this study will help guide future development and registrational efforts for FP-045 in this highly unmet patient population.”
“We are actively building our first/best-in-class oral ALDH2 franchise with multiple compounds across multiple indications, anchored by FP-045, a novel oral therapy which we are hopeful one day may become a valuable part of the PH-ILD treatment standard of care.”, stated Dr. Ben Chien, Foresee’s Chairman and CEO.
For full release please visit www.foreseepharma.com